Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive FMT for Primary Hypertension
NCT05608447Phase 1Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of allogeneic fecal microbiota in primary hypertension, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Change in Office Systolic Blood Pressure at 8 weeks. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
primary hypertension
Beyond the preview
Go deeper on NCT05608447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608447.